凝血因子Ⅱ(F2)活性蛋白
[ PROPERTIES ]
Source: Prokaryotic expression. Host: E. coli
Residues: Ser201~Arg323
Tags: N-terminal His-tag
Purity: >95%
Buffer Formulation: 20mM Tris, 150mM NaCl, pH8.0, containing 0.05% sarcosyl
and 5% trehalose. Applications: Cell culture; Activity Assays. (May be suitable for use in other assays to be determined by the end user.)
Predicted isoelectric point: 4.9
Predicted Molecular Mass: 14.4kDa
Accurate Molecular Mass: 20kDa as determined by SDS-PAGE reducing conditions. Phenomenon explanation:
The possible reasons that the actual band size differs from the predicted are as
follows:
1. Splice variants: Alternative splicing may create different sized proteins from the same gene. 2. Relative charge: The composition of amino acids may affects the charge of the protein. 3. Post-translational modification: Phosphorylation, glycosylation, methylation etc. 4. Post-translation cleavage: Many proteins are synthesized as pro-proteins, and then cleaved to
give the active form. 5. Polymerization of the target protein: Dimerization, multimerization etc.
[ USAGE ]
Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0mg/mL. Do not vortex.
[ STORAGE AND STABILITY ]
Storage: Avoid repeated freeze/thaw cycles.
Store at 2-8oC for one month. Aliquot and store at -80oC for 12 months.
Stability Test: The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37oC for 48h, and no obvious degradation and precipitation wereobserved. The loss rate is less than 5% within the expiration date underappropriate storage condition.
[ SEQUENCE ]
[ ACTIVITY ]
Coagulation Factor II (F2) also commonly called pro-thrombin is a coagulationprotein in the blood stream that has many effects in the coagulation cascade. It is aserine protease that converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Besides, Protein C Inhibitor(PCI) has been identified as an interactor of F2, thus a binding ELISA assay wasconducted to detect the interaction of recombinant rat F2 and recombinant rat PCI. Briefly, F2 were diluted serially in PBS, with 0.01%BSA (pH 7.4). Duplicatesamples of 100uL were then transferred to PCI-coated microtiter wells andincubated for 2h at 37℃. Wells were washed with PBST and incubated for 1h withanti-F2 pAb, then aspirated and washed 3 times. After incubation with HRPlabelled secondary antibody, wells were aspirated and washed 3 times. With theaddition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50µL stop solution to the wells and read at 450nm immediately. The bindingactivity of of F2 and PCI was shown in Figure 1, and this effect was in a dosedependent manner.
[ IDENTIFICATION ]
[ IMPORTANT NOTE ]
The kit is designed for research use only, we will not be responsible for any issue if the kit was used in clinical diagnostic or any other procedures.
特别提示:本公司的所有产品仅可用于科研实验,严禁用于临床医疗及其他非科研用途!以实际收货产品说明书为准,网站说明书仅供参考。